Christmas is wrapped up this season at enex
This Christmas, enex is making your holiday shopping easier by offering complementary gift wrapping to any item purchased within the centre.
Our SHINE wrapping station, generously run by volunteers from the Leukemia Foundation, will operate on Level 2, Hay Street in the lead up to Christmas.
Friday 7 December: 11am – 2pm and 5pm-9pm
Saturday 7 December: 11am – 2pm
Sunday 8 December: 11am – 2pm
Friday 14 December: 11am – 2pm and 5pm-9pm
Saturday 15 December: 11am – 2pm
Sunday 16 December: 11am – 2pm
Tuesday 18 December: 11am – 2pm
Wed 19 December: 11am – 2pm
Thursday 20 December: 11am – 2pm
Friday 21 December: 11am – 2pm
Saturday 22 December: 11am – 2pm
Sunday 23 December: 11am – 2pm
The Leukaemia Foundation is the only national charity dedicated to helping those with leukaemia, lymphoma, myeloma and related blood disorders survive and then live a better quality of life.
Leukaemia, lymphoma and myeloma are all types of blood cancer and they can develop in anyone, of any age, at any time. Another 35 Australians are diagnosed each and every day. Although improved treatments and care are helping more people survive, sadly someone loses their life to blood cancer every two hours. In fact, blood cancer is the third most common cause of cancer death in Australia, claiming more lives than breast cancer or melanoma.
Each year, the Leukaemia Foundation helps more than 750 families from regional and rural Australia by providing free accommodation in our capital cities so they can access life-saving treatment at major hospitals. Our transport service also helps thousands get to and from medical appointments, driving more than one million kilometres each year to ensure people get the medicines they need to beat their blood cancer. Thanks to its supporters, the Leukaemia Foundation is also able to provide counselling, comprehensive information, education and support programs and financial assistance to help the 60,000 Australians who are currently living with a blood cancer. We are committed to supporting initiatives and research that improve health outcomes for blood cancer patients, including improved access to new drugs that may be more effective than those currently available.